ライフサイエンスコーパス: progestogen

1 (HRT) using estrogen either alone or with a progestogen.

2 nt, study design, estrogen dose, and type of progestogen.

3 gens, mineralocorticoids, glucocorticoids or progestogens.

4 steroids including androgens, estrogens, and progestogens.

5 oral contraceptives but not with injectable progestogens.

6 juvenile males, plasma Na(+), Cl(-), and the progestogen 17a,20B-dihydroxypregnenone were significant

7 Fish progestogens activated FHM nPR, with DHP being more pote

8 n alone or combined with fixed or sequential progestogens (aHRs between 0.79 and 0.86), transdermal a

9 CIL approach was demonstrated by determining progestogens altered during pregnancy and by detecting t

10 average of 24 and 23 points for long acting progestogen and combined oral contraceptive pill groups,

11 Endogenous progestogens and pharmaceutical progestins enter the env

12 act of female steroids, including estrogens, progestogens, and androgens, is key to discovering treat

13 descendant was sensitive only to androgens, progestogens, and corticosteroids.

14 Filled prescriptions for estrogens, progestogens, and statins were recorded in the 12 months

15 The relative risk for exposure to injectable progestogen contraceptives (IPCs), mostly depot medroxyp

16 a secure internet facility to a long acting progestogen (depot medroxyprogesterone acetate or levono

17 te on whether the so-called third-generation progestogens (desogestrel, gestodene, and norgestimate)

18 Progestogens do not antagonize this effect.

19 clinical and experimental evidence points to progestogens [endogenous progesterone or synthetic proge

20 However, in the absence of a progestogen, estrogens increase endometrial cancer risk

21 un that includes androgens, corticosteroids, progestogens, estrogens, estrogen metabolites, estrogen

22 Recent HT was defined as any estrogen or progestogen exposure within 60 days before the index dat

23 We have found that progestogen-facilitated lordosis of rodents is enhanced

24 Thus, age-related changes in central progestogen formation in midbrain or diencephalon may co

25 sterols, including androgens, estrogens, and progestogens from agricultural test plots.

26 Oestrogen and progestogen have the potential to influence gastro-intes

27 % CI = 0.73-0.87), and combined estrogen and progestogen (HR = 0.78; 95% CI = 0.70-0.87) HRT.

28 5% CI = 0.84-0.95), or combined estrogen and progestogen (HR = 0.82; 95% CI = 0.76-0.88) HRT was asso

29 We assessed whether different oral progestogens in hormone replacement therapy may differen

30 gens, whereas in other vertebrates the major progestogen is progesterone (P4).

31 -free, serum-free medium with or without the progestogen, medroxyprogesterone acetate (MPA; 10(-6) M)

32 progesterone and suggests non-metabolizable progestogen might represent an alternative new therapeut

33 men were randomised to receive a long acting progestogen (n=205) or combined oral contraceptive pill

34 Thus, progestogens' non-traditional actions in the VTA to enha

35 indings do not support a strong influence of progestogens on melanoma risk.

36 igated the influence of premenopausal use of progestogens on melanoma using data from E3N (Etude Epid

37 f such steroids alone or in combination with progestogens on SLE are not known.

38 d, but the influence of premenopausal use of progestogens on this cancer has never been investigated.

39 Recent studies have suggested that progestogen-only contraceptives and combined estrogen/pr

40 (CNOCs), progestogen-only pills (POPs), and progestogen-only nonoral contraceptives (PNOCs).

41 roup, women received a 3-month supply of the progestogen-only pill (75 mug desogestrel) plus a rapid

42 ypothesised that pharmacist provision of the progestogen-only pill as a bridging interim method of co

43 Progestogen-only pill exposure was associated with an in

44 Provision of a supply of the progestogen-only pill with emergency contraception from

45 on medication that could interfere with the progestogen-only pill, and willing to give contact detai

46 s), combined nonoral contraceptives (CNOCs), progestogen-only pills (POPs), and progestogen-only nono

47 Users of progestogen-only pills had an RR for first use of an ant

48 combined (HR, 0.65; 95% CI, 0.62-0.67), and progestogen-only therapy (HR, 0.59; 95% CI, 0.56-0.62).

49 combined (HR, 0.70; 95% CI, 0.68-0.72), and progestogen-only therapy (HR, 0.70; 95% CI, 0.67-0.74) w

50 Postoperative prescription of a long acting progestogen or the combined oral contraceptive pill resu

51 amic acid, mefenamic acid, combined estrogen-progestogen, or progesterone alone).

52 Around 20 progestins (also called gestagens, progestogens, or progestagens) are used today in assisti

53 f the risk potentiation by combined estrogen/progestogen oral contraceptive use or pregnancy.

54 en-only contraceptives and combined estrogen/progestogen oral contraceptives (COCs) may increase the

55 There was no heterogeneity across types of progestogens (P = 0.22), and use of multiple progestogen

56 There was no heterogeneity across types of progestogens (P=0.22), and use of multiple progestogens

57 sterectomy might make long acting reversible progestogens preferable for some.

58 than the older, so-called second-generation progestogens (principally levonorgestrel and norethindro

59 did not differ according to the estrogen or progestogen receptor status of the tumor.

60 Systemic estrogen alone or combined with a progestogen reduces the frequency of vasomotor symptoms

61 r women on estrogen alone or estrogen plus a progestogen, regardless of presence or absence of RFs.

62 (95% CI [43% 53%]) received an intrauterine progestogen, respectively, in the same periods.

63 cross steroid classes (i.e. glucocorticoids, progestogens, sex steroids), emphasizing the modularity

64 Detailed risk associations for the specific progestogens studied are also provided.

65 of estrogens at ERbeta related to actions of progestogens, such as 5alpha-pregnan-3alpha-ol-20-one (3

66 ptives, including those that contain the new progestogens, than with older oral contraceptives contai

67 s disease among long term users of oestrogen-progestogen therapies.

68 ere found among women who had used oestrogen-progestogen therapy for between five and nine years (1.1

69 estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for the treatment of o

70 The success of progestogen treatment to prevent preterm birth in a subs

71 Women randomised to a long acting progestogen underwent fewer surgical procedures or secon

72 d a modest association between self-reported progestogen use and melanoma risk (hazard ratio (HR) = 1

73 d a modest association between self-reported progestogen use and melanoma risk (Hazard Ratio (HR)=1.2

74 users, we found no relation with duration of progestogen use, age at start and last use, and time sin

75 s, we found no relationship with duration of progestogen use, age at start and last use, and time sin

76 model demonstrated the greater use of PPI by progestogen users (OR 1.50; 1.01-2.22).

77 nce of a confounding effect of sun exposure, progestogen users had lower levels of residential sun ex

78 ormone use (eg, any characteristic: estrogen+progestogen users, RR, 1.16 [95% CI, 0.91-1.47]; P=.22;

79 progestogens (P = 0.22), and use of multiple progestogens was positively associated with melanoma ris

80 f progestogens (P=0.22), and use of multiple progestogens was positively associated with melanoma ris

81 , glucocorticoids, androgens, estrogens, and progestogens were analyzed using liquid chromatography a

82 (oestrogen-only, tibolone, combined HRT and progestogen) were statistically significantly associated

83 pregnen-3-one (20beta-S) are the predominant progestogens, whereas in other vertebrates the major pro